REG - Eco Animal Health Gp - Board Appointment

ECO Animal HealthAnnouncement

12/02/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240212:nRSL6823Ca&default-theme=true

RNS Number : 6823C  Eco Animal Health Group PLC  12 February 2024

 

  ECO Animal Health Group plc

("ECO" or the "Company")

 

Appointment of Dr. Joachim Hasenmaier as Non-Executive Director

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health
company with a portfolio of marketed veterinary products and a maturing
proprietary R&D pipeline, announces the appointment of Dr. Joachim
Hasenmaier as a Non-Executive Director, with immediate effect.

Dr. Hasenmaier is a highly experienced commercial leader with more than two
decades in the international animal health industry. From 2001 to 2019 he held
a variety of senior roles within the animal health division at Boehringer
Ingelheim, concluding as member of the Board of Managing Directors responsible
for the entire animal health division. During this time he led successful
transformation initiatives including the integration of the former Sanofi
animal health business Merial, spearheaded key product launches and supported
rapid global growth and expansion.

Dr. Andrew Jones, Chairman of ECO, commented: "On behalf of the Board, I am
delighted to welcome Joachim as a Non-Executive Director to ECO. He has a
wealth of sector and board experience, and I am confident that his strong
track record of delivering sales growth and driving performance will be hugely
beneficial to the growth of the Company. We are excited about what 2024 holds
as we look to maximise the potential of our broad commercial and R&D
portfolio and expand our business both organically and via new opportunities."

Dr. Joachim Hasenmaier, incoming Non-Executive Director of ECO, added: "ECO
Animal Health is at a pivotal time in its development. The Company is well
positioned to capitalise on the future growth opportunities offered by its
innovative, focused pipeline of vaccines and biologics. I look forward to
working closely with the Board to drive the next phase of growth as a
sector-leading pioneer in animal health."

Dr. Hasenmaier has also served as Chairman of the Board at IMV Technologies
since 2022 and as a Member of the Supervisory Boards of Invetx. He served on
the Board of NASDAQ-listed Heska prior to its acquisition by Mars Petcare. He
also held senior positions at Hoechst Roussel Vet and McKinsey & Company.

Dr. Hasenmaier is a Doctor of Veterinary Medicine and holds a PhD in
Immunology from Ludwig-Maximillians University in Munich. has an MBA from
Northwestern University, USA.

Additional Information on the Board Appointment

The following additional information is provided with regards to the
appointment of Joachim Alfred Hasenmaier, aged 64, in accordance with AIM Rule
17 and Schedule 2(g) of the AIM Rules for Companies:

Current directorships/partnerships:

·    Invetx, Inc.

·    Minotaur Invest (holding company for IMV Technologies)

·    Phagelux Agrihealth

Directorships/partnerships within the last five years:

·    Heska Corporation

·    Boehringer Ingelheim Corporate Center GMBH

·    Boehringer AG

·    Boehringer Ingelheim GMBH

·    C.H. Boehringer Sohn AG & Co. KG

·    Profunda Verwaltungsgesellschaft MBH & Co KG

·    Boehringer Ingelheim Deutschland GMBH

·    Boehringer Ingelheim Vetmedica GMBH

·    Boehringer Ingelheim International GMBH

·    Boehringer Ingelheim Verwaltungs GMBH

·    Boehringer Ingelheim Auslandsbeteiligungs GMBH

There are no further disclosures required to be made in respect of the
appointment under AIM Rule 17 and Schedule 2(g) of the AIM Rules for
Companies.

-Ends-

For further information please contact:

 

 ECO Animal Health Group plc                                    020 8447 8899

 David Hallas (CEO)

 Christopher Wilks (CFO)
 Singer Capital Markets (Nominated Adviser & Joint Broker)      020 7496 3000

 Phil Davies

 Sam Butcher
 Investec (Joint Broker)                                        020 7597 5970

 Gary Clarence

 Lydia Zychowska
 Equity Development                                             020 7065 2692

 Hannah Crowe

 Matt Evans
 ICR Consilium (Financial PR)                                   020 3709 5700

 Mary-Jane Elliott                                              ecoanimalhealth@consilium-comms.com

 Jessica Hodgson

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing
branded veterinary pharmaceuticals globally, with expertise in antibiotics and
vaccines for pigs and poultry. We have a maturing proprietary R&D
pipeline.

Headquartered in the UK, with global offices including R&D and
manufacturing, we have marketing authorisations in over 70 countries and
employ over 200 people worldwide.

Our lead product, Aivlosin® is a proprietary, patented medication which is
effective against both respiratory and intestinal diseases in pigs and
poultry.

Click here for more information: https://ecoanimalhealth.com
(https://ecoanimalhealth.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAUPUQAPUPCGGB